Objective To analyze the effects of paroxetine combined with pramipexole on serum cystatin C（CysC）and interleukin-1β（IL-1β） in Parkinson’s patients.Methods One hundred and twenty-eight Parkinson’s patients treated in a hospital in Xinmi from October 2018 to December 2020 were selected for the study and were divided into single-drug group（64 cases） and combination group（64 cases） using the random number table method.Patients in the single-drug group were given pramipexole treatment and patients in the combination drug group were given paroxetine combined with pramipexole.Both groups were treated for 8 weeks.The clinical efficacy

occurrence of adverse effects

Hamilton Depression Rating Scale（HAMD） scores

serum CysC and IL-1β levels were compared between the two groups before and after treatment.Results The overall treatment efficiency of the patients in the combination group was 96.87%

which was higher than that of the single-drug group（78.12%）.and the difference was statistically significant（χ

2

=10.286

P=0.001）.Before

treatment

there was no statistically significant difference between the HAMD scores of the 2 groups（P

>

0.05）;after treatment

the HAMD scores of the 2 groups were significantly lower than before treatment

and the combination group had a significantly lower score than the single-drug group（P

<

0.05）.Before treatment

there was no statistically significant difference between the serum CysC and IL-1β levels of the two groups（P

>

0.05）;after treatment

the serum CysC and IL-1β levels of the two groups were significantly lower than before treatment

and the combination group had significantly lower levels than the single drug group（P

<

0.05）.The incidence of adverse reactions was 6.25 % in the combination group

which was higher than that of 4.69% in the single-drug group

but the difference was not statistically significant（P

>

0.05）.Conclusion Paroxetine combined with pramipexole treatment can effectively relieve depressive symptoms and reduce serum CysC and IL-1β levels in patients with Parkinson’s disease with fewer adverse effects and higher safety

which is worthy of wider clinical application.